TransMedics Group (NASDAQ:TMDX) Price Target Raised to $180.00 at Piper Sandler

TransMedics Group (NASDAQ:TMDX) had its target price hoisted by Piper Sandler from $170.00 to $180.00 in a report issued on Thursday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other equities analysts have also recently issued reports on TMDX. Cantor Fitzgerald began coverage on TransMedics Group in a report on Thursday, June 6th. They issued an overweight rating and a $161.00 price target on the stock. Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an outperform rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an overweight rating in a research report on Wednesday, May 1st. TD Cowen increased their price target on TransMedics Group from $130.00 to $175.00 and gave the company a buy rating in a research note on Friday, June 7th. Finally, Canaccord Genuity Group upped their target price on TransMedics Group from $117.00 to $169.00 and gave the company a buy rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $163.50.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX traded down $1.05 during mid-day trading on Thursday, hitting $150.46. The company had a trading volume of 746,078 shares, compared to its average volume of 756,267. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of -445.62 and a beta of 1.99. The firm’s 50 day simple moving average is $143.82 and its two-hundred day simple moving average is $110.58. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $171.98. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 17.37% and a net margin of 0.84%. The firm’s quarterly revenue was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) EPS. As a group, equities research analysts forecast that TransMedics Group will post 0.81 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Stephen Gordon sold 15,000 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $128.00, for a total transaction of $1,920,000.00. Following the completion of the transaction, the chief financial officer now owns 23,299 shares in the company, valued at $2,982,272. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $128.00, for a total transaction of $1,920,000.00. Following the completion of the transaction, the chief financial officer now owns 23,299 shares in the company, valued at $2,982,272. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The disclosure for this sale can be found here. In the last three months, insiders have sold 101,342 shares of company stock valued at $13,642,015. 7.00% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

Several hedge funds and other institutional investors have recently bought and sold shares of TMDX. Venturi Wealth Management LLC purchased a new position in shares of TransMedics Group in the first quarter valued at approximately $30,000. Fidelis Capital Partners LLC acquired a new stake in TransMedics Group in the first quarter valued at $35,000. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group during the second quarter worth about $47,000. J.Safra Asset Management Corp lifted its position in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after acquiring an additional 383 shares during the period. Finally, Signaturefd LLC increased its stake in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.